Feb. 15, 2021
Here is the link.
This is a detailed account of my lost in geron, in September of 2018. This was a very pivotal learning experience from me and influenced my trading styles to this day and learning also to properly manage my risks and have a real strategy in place. Geron Corporation, located in Menlo Park, Calif., announced that Janssen Pharmaceutical Inc., a Johnson & Johnson company, has terminated their 2014 Collaboration and License Agreement. The two companies had teamed up to develop and commercialize imetelstat, a first-in-class telomerase inhibitor, for myelofibrosis and myelodysplastic syndromes. The effective date of termination, under the collaboration deal, is September 28, 2018. At that time, the rights licensed to the imetelstat program, which includes any intellectual property rights created via the collaboration, return to Geron. Janssen will have no further obligations to fund any of the ongoing clinical trials. The transition will take place over approximately 12 months with operational assistance from Janssen. Janssen will supply imetelstat to Geron for up to two years. Two clinical trials of imtelstat, IMbark for myelofibrosis and IMerge for myelodysplastic syndromes, will continue. “We believe the clinical results from IMbark provide valuable insights into the potential future development of imetelstat for an underserved relapsed and refractory myelofibrosis patient population. We also believe the combined data of 38 patients from the initial and expansion cohorts for the target patient population from the Phase II portion of IMerge support further development of imetelstat, and we are therefore prioritizing the initiation of the Phase III portion of IMerge.”